Page last updated: 2024-12-07

levalbuterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Levalbuterol: The R-isomer of albuterol. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123600
CHEMBL ID1002
CHEBI ID8746
SCHEMBL ID4003
MeSH IDM0359590

Synonyms (83)

Synonym
BIDD:GT0508
STK618645
AKOS005552518
xopenex
r-albuterol
(-)-alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol
1,3-benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (alpha1r)-
1,3-benzenedimethanol, alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (-)-
(r)-alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol
m-xylene-alpha,alpha'-diol, alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-, (r)-(-)-
(r)-alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol
NCGC00015955-01
NCGC00024698-01
tocris-0634
lopac-s-8260
NCGC00015955-02
lopac-s-5013
cas-18559-94-9
NCGC00016736-01
alpha-1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol
levalbuterol
34391-04-3
r-salbutamol
(-)-salbutamol
levosalbutamol
(r)-albuterol
CHEBI:8746 ,
4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
(r)-salbutamol
(-)-albuterol
asf-1096
albuterol (r)-form
CHEMBL1002
levosalbutamol (inn)
D08124
68H ,
A822211
4-[(1r)-2-(tert-butylamino)-1-hydroxy-ethyl]-2-(hydroxymethyl)phenol
BBL010806
NCGC00015955-03
edn2nbh5ss ,
unii-edn2nbh5ss
levosalbutamol [inn]
levolin
bdbm50361247
levosalbutamol [who-dd]
levosalbutamol [mart.]
albuterol (r)-form [mi]
levalbuterol [vandf]
(r)-.alpha.(sup 1)-((tert-butylamino)methyl)-4-hydroxy-m-xylene-.alpha.,.alpha.'-diol
BRD-K34469523-003-01-4
salbutamol (hemisulfate)
SCHEMBL4003
NDAUXUAQIAJITI-LBPRGKRZSA-N
F2173-0564
(r)-4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol
(l)-albuterol
DTXSID80187964 ,
AC-1542
(r) - albuterol
J-019582
SBI-0206903.P001
gtpl9816
DB13139
Q408709
albuterol; ah-3365; (r)-albuterol; r-albuterol; r albuterol
BCP28425
(-)-albuterol sulfate (1
324000-04-6
albuterol (hemisulfate);ah-3365 (hemisulfate)
(r)-albuterol;(r)-salbutamol;levosalbutamol
HY-B1675
CS-0013639
GLXC-25242
EN300-1699072
dtxcid40110455
levalbuterol inhalation
levalbuterol inhalation 0.63mg/3ml
levosalbutamol (mart.)
levalbuterol inhalation 1.25mg/3ml
levalbuterol inhalation 0.31mg/3ml
levosalbutamolum
4-((1r)-2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol

Research Excerpts

Overview

Levalbuterol is a cost-saving option for treating hospitalized patients with COPD.

ExcerptReferenceRelevance
"Levalbuterol is a cost-saving option for treating hospitalized patients with COPD in China."( Levalbuterol
Chen, L; Chen, X; Hu, Y; Li, X; Zhi, C,
)
3.02

Dosage Studied

ExcerptRelevanceReference
"5 mg four times daily (n = 57); dosage reductions and other respiratory therapies were permitted."( Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma.
Brunetti, L; Dhanaliwala, F; Kang, H; Poiani, G; Poppiti, K; Suh, DC, 2015
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
albuterolA member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NFKB1 protein, partialHomo sapiens (human)Potency6.30960.02827.055915.8489AID895; AID928
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency0.33700.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.80660.001318.074339.8107AID926; AID938
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency1.25890.00207.533739.8107AID891
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)Ki4.70080.00000.66359.5499AID637822; AID637826; AID637878
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)EC50 (µMol)0.29230.00000.311110.0000AID637823; AID637877; AID637879
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID637877Agonist activity at recombinant human beta2 adrenoceptor expressed in HEK293T cells assessed as increase in IBMX-induced cAMP accumulation using [3H]-cAMP after 30 mins by liquid scintillation counting in presence of 100 uM boric acid2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637826Displacement of [3H]-DHA from recombinant human beta2 adrenoceptor expressed in HEK293T cells in presence of 100 uM boric acid2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637878Displacement of [3H]-DHA from recombinant human beta2 adrenoceptor expressed in HEK293T cells in presence of 100 uM phenylboronic acid2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637879Agonist activity at recombinant human beta2 adrenoceptor expressed in HEK293T cells assessed as increase in IBMX-induced cAMP accumulation using [3H]-cAMP after 30 mins by liquid scintillation counting in presence of 100 uM phenylboronic acid2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637822Displacement of [3H]-DHA from recombinant human beta2 adrenoceptor expressed in HEK293T cells2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637824Agonist activity at recombinant human beta2 adrenoceptor expressed in HEK293T cells assessed as increase in IBMX-induced cAMP accumulation using [3H]-cAMP after 30 mins by liquid scintillation counting relative to isoproterenol2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637880Agonist activity at recombinant human beta2 adrenoceptor expressed in HEK293T cells assessed as increase in IBMX-induced cAMP accumulation using [3H]-cAMP after 30 mins by liquid scintillation counting in presence of 100 uM boric acid relative to compound2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637881Agonist activity at recombinant human beta2 adrenoceptor expressed in HEK293T cells assessed as increase in IBMX-induced cAMP accumulation using [3H]-cAMP after 30 mins by liquid scintillation counting in presence of 100 uM phenylboronic acid relative to 2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID637884Ratio of compound EC50 in presence of 100 uM boric acid to compound EC50 for recombinant human beta2 adrenoceptor expressed in HEK293T cells2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637883Selectivity for human beta2 adrenoceptor expressed in CHO-K1 cells over human beta3 adrenoceptor expressed in CHO-K1 cells2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637823Agonist activity at recombinant human beta2 adrenoceptor expressed in HEK293T cells assessed as increase in IBMX-induced cAMP accumulation using [3H]-cAMP after 30 mins by liquid scintillation counting2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637885Ratio of compound EC50 in presence of 100 uM phenylboronic acid to compound EC50 for recombinant human beta2 adrenoceptor expressed in HEK293T cells2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637825Ratio of compound Ki to isoproterenol Ki for recombinant human beta2 adrenoceptor expressed in HEK293T cells2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID637882Selectivity for human beta2 adrenoceptor expressed in CHO-K1 cells over human beta1 adrenoceptor expressed in CHO-K1 cells2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
AID70530Free energy of binding to turkey erythrocyte beta receptor1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Mapping the turkey erythrocyte beta receptor: a distance geometry approach.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346250Human beta2-adrenoceptor (Adrenoceptors)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.55)18.7374
1990's0 (0.00)18.2507
2000's1 (4.55)29.6817
2010's10 (45.45)24.3611
2020's10 (45.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 76.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index76.89 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index131.72 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (76.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (20.83%)5.53%
Reviews3 (12.50%)6.00%
Case Studies3 (12.50%)4.05%
Observational1 (4.17%)0.25%
Other12 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]